Luc J.I. Zimmermann

Prof. Dr. Luc J.I. Zimmermann

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2018 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
RGRuth Gussenhoven
Ruth Gussenhoven
RWRob J. J. Westerlaken
Rob J. J. Westerlaken
DODaan Ophelders
Daan Ophelders
AJAlan H Jobe
Alan H Jobe
MKMatthew W. Kemp
Matthew W. Kemp
Tim WolfsTim Wolfs
Tim Wolfs
Antenatal infection (i.e., chorioamnionitis) is an important risk factor for adverse neurodevelopmental outcomes after preterm birth. Destructive and developmental disturbances of the white matter are hallmarks of preterm brain injury. Understanding the temporal effects of antenatal infection in relation to the onset of neurological injury is crucial for the development of neurotherapeutics for preterm infants. However, these dynamics remain unstudied. Time-mated ewes were intra-amniotically injected with lipopolysaccharide at 5, 12, or 24 h or 2, 4, 8, or 15 days before preterm delivery at 125 days gestational age (term ~ 150 days). Post mortem analyses for peripheral immune activation, neuroinflammation, and white matter/neuronal injury were performed. Moreover, considering the neuroprotective potential of erythropoietin (EPO) for perinatal brain injury, we evaluated (phosphorylated) EPO receptor (pEPOR) expression in the fetal brain following LPS exposure. Intra-amniotic exposure to this single bolus of LPS resulted in a biphasic systemic IL-6 and IL-8 response. In the developing brain, intra-amniotic LPS exposure induces a persistent microgliosis (IBA-1 immunoreactivity) but a shorter-lived increase in the pro-inflammatory marker COX-2. Cell death (caspase-3 immunoreactivity) was only observed when LPS exposure was greater than 8 days in the white matter, and there was a reduction in the number of (pre) oligodendrocytes (Olig2- and PDGFRα-positive cells) within the white matter at 15 days post LPS exposure only. pEPOR expression displayed a striking biphasic regulation following LPS exposure which may help explain contradicting results among clinical trials that tested EPO for the prevention of preterm brain injury. We provide increased understanding of the spatiotemporal pathophysiological changes in the preterm brain following intra-amniotic inflammation which may aid development of new interventions or implement interventions more effectively to prevent perinatal brain damage.

29 December 2020 in Pediatric Cardiology
Verified
Journal Article
Open access
PDF file
MBMelinda Barkhuizen
Melinda Barkhuizen
RARaul Abella
Raul Abella
JVJ. S. Hans Vles
J. S. Hans Vles
LZLuc J.I. Zimmermann
Luc J.I. Zimmermann
DGDiego Gazzolo
Diego Gazzolo
DGDanilo AW Gavilanes
Danilo AW Gavilanes
Congenital heart defects (CHD) is one of the most common types of birth defects. Thanks to advances in surgical techniques and intensive care, the majority of children with severe forms of CHD survive into adulthood. However, this increase in survival comes with a cost. CHD survivors have neurological functioning at the bottom of the normal range. A large spectrum of central nervous system dysmaturation leads to the deficits seen in critical CHD. The heart develops early during gestation, and CHD has a profound effect on fetal brain development for the remainder of gestation. Term infants with critical CHD are born with an immature brain, which is highly susceptible to hypoxic-ischemic injuries. Perioperative blood flow disturbances due to the CHD and the use of cardiopulmonary bypass or circulatory arrest during surgery cause additional neurological injuries. Innate patient factors, such as genetic syndromes and preterm birth, and postoperative complications play a larger role in neurological injury than perioperative factors. Strategies to reduce the disability burden in critical CHD survivors are urgently needed.

4 April 2024 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Open access
CAChris H.P. van den Akker
Chris H.P. van den Akker
NENicholas D. Embleton
Nicholas D. Embleton
Alexandre LapillonneAlexandre Lapillonne
Alexandre Lapillonne
WMWalter Mihatsch
Walter Mihatsch
SSsilvia salvatore
silvia salvatore
HSHania Szajewska
Hania Szajewska
The recent advisory issued by the United States Food and Drug Administration, cautioning against the routine administration of probiotics in preterm neonates, has sparked a lively debate within the scientific community. This commentary presents a perspective from members of the Special Interest Group on Gut Microbiota and Modifications within the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and other authors who contributed to the ESPGHAN position paper on probiotics for preterm infants, as well as representatives from the European Foundation for the Care of Newborn Infants. We advocate for a more nuanced and supportive approach to the use of certain probiotics in this vulnerable population, balancing the demonstrated benefits and risks.

2 February 2016 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
DODaan Ophelders
Daan Ophelders
RGRuth Gussenhoven
Ruth Gussenhoven
MLMartin Lammens
Martin Lammens
BKBenno Küsters
Benno Küsters
MKMatthew W. Kemp
Matthew W. Kemp
Tim WolfsTim Wolfs
Tim Wolfs
Intra-amniotic Candida albicans (C. Albicans) infection is associated with preterm birth and high morbidity and mortality rates. Survivors are prone to adverse neurodevelopmental outcomes. The mechanisms leading to these adverse neonatal brain outcomes remain largely unknown. To better understand the mechanisms underlying C. albicans-induced fetal brain injury, we studied immunological responses and structural changes of the fetal brain in a well-established translational ovine model of intra-amniotic C. albicans infection. In addition, we tested whether these potential adverse outcomes of the fetal brain were improved in utero by antifungal treatment with fluconazole. Pregnant ewes received an intra-amniotic injection of 107 colony-forming units C. albicans or saline (controls) at 3 or 5 days before preterm delivery at 0.8 of gestation (term ~ 150 days). Fetal intra-amniotic/intra-peritoneal injections of fluconazole or saline (controls) were administered 2 days after C. albicans exposure. Post mortem analyses for fungal burden, peripheral immune activation, neuroinflammation, and white matter/neuronal injury were performed to determine the effects of intra-amniotic C. albicans and fluconazole treatment. Intra-amniotic exposure to C. albicans caused a severe systemic inflammatory response, illustrated by a robust increase of plasma interleukin-6 concentrations. Cerebrospinal fluid cultures were positive for C. albicans in the majority of the 3-day C. albicans-exposed animals whereas no positive cultures were present in the 5-day C. albicans-exposed and fluconazole-treated animals. Although C. albicans was not detected in the brain parenchyma, a neuroinflammatory response in the hippocampus and white matter was seen which was characterized by increased microglial and astrocyte activation. These neuroinflammatory changes were accompanied by structural white matter injury. Intra-amniotic fluconazole reduced fetal mortality but did not attenuate neuroinflammation and white matter injury. Intra-amniotic C. albicans exposure provoked acute systemic and neuroinflammatory responses with concomitant white matter injury. Fluconazole treatment prevented systemic inflammation without attenuating cerebral inflammation and injury.

1 May 2014 in Brain Research
Verified
Journal Article
Closed access
KCK.E.M. Cox-Limpens
K.E.M. Cox-Limpens
DGDanilo AW Gavilanes
Danilo AW Gavilanes
LZLuc J.I. Zimmermann
Luc J.I. Zimmermann
JVJ.S.H. Vles
J.S.H. Vles

8 December 2020 in Acta Paediatrica
Verified
Journal Article
Open access
PDF file
VLVerena Lindacher
Verena Lindacher
PAPhiline Altebaeumer
Philine Altebaeumer
NMNeil Marlow
Neil Marlow
VMValerie Matthaeus
Valerie Matthaeus
ISIris Nikola Straszewski
Iris Nikola Straszewski
TMthe European Standards of Care for Newborn Health project members
the European Standards of Care for Newborn Health project members
Aim: Among children who receive hospital care, preterm infants are Europe's largest group, whose numbers are continually increasing. Currently, no pan‐European standards of care for preterm or critically ill infants are available, except for a few specific topics, and practices vary widely in different regions.Methods: The European Foundation for the Care of Newborn Infants (EFCNI) has initiated a transdisciplinary collaboration project to provide agreed standards for high‐quality perinatal and neonatal care, whose implementation will ensure fairer and more equitable care across Europe. This will improve care for these vulnerable infants and their families, ameliorate the long‐term conditions found in preterm and critically ill infants and enhance the quality of family life of affected families. More than 220 experts—healthcare professionals, patient representatives and other relevant stakeholders—have come together for the first time to develop a broad reference guidance in neonatology and associated fields.Results: Ninety‐six standards on 11 overarching topic areas were developed and endorsed.Conclusion: This reference framework serves as a basis for the development of binding national standards for high‐quality care. A robust translation and implementation strategy is facilitated, with the goal of improved health outcomes following preterm birth all around Europe.